68ga labeled her2 affibody
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2022 (NCT05411432)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2BINDING AGENT
ERBB2 binding agent
Chemistry & pharmacology
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06289517 | N/A | Apr 1, 2024 | Peking University |
| NCT05411432 | Early Phase 1 (Phase 1) | Jun 1, 2022 | Xijing Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1